Who are Tenaya Therapeutics, Inc.'s main suppliers?

Tenaya Therapeutics, Inc. (TNYA) key suppliers include: REGENXBIO Inc., Sanofi, Sanofi. View the full supplier network at chainsifter.com/chain/TNYA.

Who are Tenaya Therapeutics, Inc.'s major customers?

Tenaya Therapeutics, Inc. (TNYA) key customers include: ALNYLAM, Alnylam Pharmaceuticals, Inc., Alnylam Pharmaceuticals, Inc., REGENXBIO Inc., Sanofi and 3 more. View the full customer network at chainsifter.com/chain/TNYA.

What sector is Tenaya Therapeutics, Inc. in?

Tenaya Therapeutics, Inc. (TNYA) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

Tenaya Therapeutics, Inc. Supplier List (TNYA): 3 Verified Suppliers

3Suppliers

8Customers

3Debt Items

20Related Chains

Source-Backed Evidence Depth

Tenaya Therapeutics, Inc. (TNYA) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

15Total relationships

3Distinct source URLs

5High confidence

0.767Average confidence

2026-09-13Latest database update

ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

Tenaya Therapeutics, Inc. Suppliers

Ticker	Name	Confidence	Evidence
RGNX	REGENXBIO Inc.	72%	Reciprocal relationship from RGNX graph: Reciprocal relationship from TNYA graph: Reciprocal relationship from RGNX graph: atent that will expire in 2034, one issued U.S. patent that will expire in 2…
SNYNF	Sanofi	72%	. We may in the future pursue invalidity proceedings with respect to third-party patents. The outcome following legal assertions of invalidity is unpredictable. Even if resolved in our favor, these l…
SNYNF	Sanofi	72%	Reciprocal relationship from SNYNF graph: Reciprocal relationship from TNYA graph: . We may in the future pursue invalidity proceedings with respect to third-party patents. The outcome following lega…

Tenaya Therapeutics, Inc. Customers

Ticker	Name	Confidence	Evidence
ALNYLAM	ALNYLAM	90%	Pursuant to the terms of the Collaboration Agreement, Alnylam will pay the Company an upfront payment of up to $10.0 million within thirty (30) days after Alnylam’s receipt of an invoice from the Company.
ALNY	Alnylam Pharmaceuticals, Inc.	72%	occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). Contract Liabilities Contract liabilities consist pr…
ALNY	Alnylam Pharmaceuticals, Inc.	72%	Reciprocal relationship from ALNY graph: Reciprocal relationship from TNYA graph: occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisf…
RGNX	REGENXBIO Inc.	72%	Reciprocal relationship from RGNX graph: atent that will expire in 2034, one issued U.S. patent that will expire in 2038, one issued U.S. patent that will expire in 2039, one issued U.S. patent that …
SNYNF	Sanofi	72%	. We may in the future pursue invalidity proceedings with respect to third-party patents. The outcome following legal assertions of invalidity is unpredictable. Even if resolved in our favor, these l…
SNYNF	Sanofi	72%	Reciprocal relationship from SNYNF graph: Reciprocal relationship from TNYA graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from TNYA graph: Reciprocal relationship from SNYN…
CAPITAL-RESOURCES	CAPITAL-RESOURCES	62%	do not allocate our costs by research program, product candidate or proprietary platform technology, as a significant amount of research and development expenses represent internal costs, which are d…
CATALYST-PHARMS-INC	CATALYST-PHARMS-INC	62%	atio for its proposed indication is acceptable; • the FDA, EMA or other comparable foreign regulatory authorities may fail to approve the manufacturing processes, test procedures and specifications o…

Tenaya Therapeutics, Inc. Debt Obligations

Instrument	Description	Confidence	Evidence
TNYA-DEBT	Debt stack $10.1M	90%	Market cache reports total debt of $10.1M.
TNYA-DEBT-13047	Warrants outstanding: 2289000	90%	xbrl warrant detail from xbrl 2025-12-31.
TNYA-DEBT-13048	Xbrl Convertible	90%	xbrl convertible detail from xbrl 2024-12-31.

Tenaya Therapeutics, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Tenaya Therapeutics, Inc..

Tenaya Therapeutics, Inc. Ownership

Holder	Name	Confidence	Evidence
TNYA-OWNER-VANGUARD-CAPITAL-MANAGEMENT-LLC	VANGUARD CAPITAL MANAGEMENT LLC	90%	13F overlay lists VANGUARD CAPITAL MANAGEMENT LLC as top holder; 105 tracked holders.

Tenaya Therapeutics, Inc. Extended Supply Chain Network

Ticker	Name	Chain Index	Hops
REGN	Regeneron Pharmaceuticals, Inc.	100.00	2
CALC	CalciMedica, Inc.	100.00	2
EDIT	Editas Medicine, Inc.	100.00	2
ATOS	Atossa Therapeutics, Inc.	100.00	2
SVA	Sinovac Biotech Ltd.	100.00	2
CYTOF	Altamira Therapeutics Ltd.	100.00	2
BLRX	BioLineRx Ltd.	100.00	2
BIOA	BioAge Labs, Inc.	100.00	2
ANRO	Alto Neuroscience, Inc.	100.00	2
CBIO	Crescent Biopharma, Inc.	100.00	2
ALXO	ALX Oncology Holdings Inc.	100.00	2
CCEP	Coca-Cola Europacific Partners PLC	100.00	2
DSGN	Design Therapeutics, Inc.	100.00	2
AZN	AstraZeneca PLC	100.00	2
VEEV	Veeva Systems Inc.	100.00	2
ANL	Adlai Nortye Ltd.	100.00	2
DYN	Dyne Therapeutics, Inc.	100.00	2
DBVTF	DBV TECHNOLOGIES	100.00	2
CYTK	Cytokinetics, Incorporated	100.00	2
NVO	Novo Nordisk A/S	100.00	2

Tenaya Therapeutics, Inc. Supply Chain